Homology Medicines, Inc. (FIXX)
| Market Cap | 31.28M |
| Revenue (ttm) | 1.96M |
| Net Income (ttm) | -131.14M |
| Shares Out | 57.93M |
| EPS (ttm) | -2.28 |
| PE Ratio | n/a |
| Forward PE | 22.27 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 3,420 |
| Open | 0.531 |
| Previous Close | 0.545 |
| Day's Range | 0.531 - 0.561 |
| 52-Week Range | 0.458 - 1.760 |
| Beta | -0.23 |
| Analysts | Buy |
| Price Target | 7.63 (+1,312.96%) |
| Earnings Date | Nov 14, 2023 |
About FIXX
Homology Medicines, Inc., a genetic medicines company, focuses on transforming the lives of patients suffering from rare genetic diseases. Its proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a nuclease-free gene editing mobility, gene therapy or for various genetic disorders. The company's various set of AAVHSCs allows company to precisely target, through a single injection, a range of disease-relevant tissues, incl... [Read more]
Financial Performance
In 2022, FIXX's revenue was $3.21 million, a decrease of -90.56% compared to the previous year's $33.97 million. Losses were -$5.01 million, -94.77% less than in 2021.
Financial StatementsAnalyst Forecast
According to 4 analysts, the average rating for FIXX stock is "Buy." The 12-month stock price forecast is $7.63, which is an increase of 1,312.96% from the latest price.
News
HOMOLOGY MEDICINES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Homology Medicines, Inc. - FIXX
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of Homology Medic...
FIXX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Homology Medicines, Inc. Is Fair to Shareholders
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of Homology Medicines, Inc. (NASDAQ: FIXX) and Q32 Bio Inc. is fair to Homology shareholde...
Q32 Bio and Homology Medicines Announce Merger Agreement
--The combined company will operate as Q32 Bio Inc., advancing the development of Q32 Bio's two clinical development candidates, bempikibart (ADX-914) in Phase 2 for the treatment of atopic dermatitis...
Homology Medicines Reports Third Quarter 2023 Financial Results
- Continuing to Evaluate Strategic Options for the Company and the Pipeline of Genetic Medicines, including HMI-103 -
SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Homology Medicines, Inc. (NASDAQ: FIXX) and Encourages Long-Term Investors to Contact the Firm - FIXX
PHILADELPHIA , Aug. 16, 2023 /PRNewswire/ -- Kaskela Law LLC announces that it is investigating Homology Medicines, Inc. ("Homology" or the "Company") (NASDAQ: FIXX) on behalf of the Company's long-te...
Homology Medicines Announces Encouraging Initial Data from First Dose Level in the pheEDIT Trial Evaluating Gene Editing Candidate HMI-103 in Adults with Classical PKU
Participant 1 Achieved Clinically Meaningful Reduction in Plasma Phe of Up to 99% Change from Baseline and Below the U.S. PKU Treatment Guideline Threshold (
Homology Medicines Announces First Data from IND-Enabling Studies with GTx-mAb Candidate HMI-104 for PNH, Which Demonstrated Sustained Expression of Functional C5mAb Levels, at the ASGCT Annual Meeting
- New Preclinical Data Demonstrated Ability to Re-Dose with AAVHSCs Across Viral Clades, Potentially Expanding Possibilities of Genetic Medicine Programs in the Future -
Homology Medicines Reports First Quarter 2023 Financial Results and Recent Highlights
- On Track to Report Initial Clinical Data from pheEDIT PKU Gene Editing Trial Mid-Year 2023 -
Homology Medicines Announces Upcoming Presentations Highlighting its Genetic Medicines Platform, including New Data from IND-Enabling Studies with GTx-mAb Development Candidate HMI-104 for PNH, at ASGCT Annual Meeting
- First Preclinical Data Sets Demonstrating Potential to Re-Dose with AAVHSCs and to Identify Genomic Sites with Improved Gene Editing Integration Efficiency -
Homology Medicines Announces Presentations on Design of Ongoing Gene Editing and Gene Therapy Trials for PKU and Hunter Syndrome at ACMG Annual Clinical Genetics Meeting
BEDFORD, Mass., March 15, 2023 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced two presentations during the ACMG Annual Clinical Genetics Meeting, w...
Homology Medicines Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Highlights
- On Track to Provide Initial Clinical Data from Gene Editing Trial for PKU Mid-Year with First Participant Dosed and Others in Screening -
Homology Medicines Announces Promotion of Julie Jordan, M.D., to Chief Medical Officer
BEDFORD, Mass., March 09, 2023 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today that Julie Jordan, M.D., has been promoted to Chief Medical Off...
Homology Medicines to Participate in the 43rd Annual Cowen Healthcare Conference
BEDFORD, Mass., March 02, 2023 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today that Albert Seymour, Ph.D., President and Chief Executive Offic...
Homology Medicines Presents Preclinical Data Supporting Immunosuppression Regimen in Ongoing PKU and Hunter Syndrome Clinical Trials, and Details Optimized MLD Gene Therapy Candidate at the 19th Annual WORLDSymposium™ Meeting
Preclinical Studies Demonstrated a Targeted Immunosuppression Approach Led to Reduced Immune Response to AAVHSC Administration and Improved Gene Expression
Homology Medicines Provides Update on pheEDIT and juMPStart Clinical Trials and Announces Expected 2023 Milestones, Including Initial Data Read-Outs from Both Programs
Strong Cash Position with Runway into Fourth Quarter 2024
Homology Medicines Reports Third Quarter 2022 Financial Results and Recent Highlights
- On Track for Updates on pheEDIT and juMPStart Programs by Year-End -
Homology Medicines Presents on Design of pheEDIT Trial Evaluating One-Time Nuclease-Free Gene Editing Candidate HMI-103 for PKU at American Society of Human Genetics Meeting
- Additional Presentation Focused on Use of Single-Molecule, Modified Base Sequencing to Support Vector Design -
Homology Medicines to Participate at Upcoming Conferences
BEDFORD, Mass., Oct. 06, 2022 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a clinical-stage genetic medicines company, announced today participation at the following conferences.
Homology Medicines Appoints Albert Seymour, Ph.D., Chief Executive Officer
Arthur Tzianabos, Ph.D., Named Chairperson of the Board of Directors
Homology Medicines Reports Second Quarter 2022 Financial Results, Recent Highlights and Provides Business Update
- On Track for Updates on pheEDIT and juMPStart Programs by End of 2022 -
Homology Medicines Announces Optimized, In Vivo Gene Therapy Candidate for the Treatment of Metachromatic Leukodystrophy
- Candidate Showed Ability to Target Central Nervous System and Peripheral Organs Following a Single I.V. Administration in MLD Model, a Key Differentiator from Available Treatments and Product Candid...
Homology Medicines Announces Peer-Reviewed Publication on Novel Discovery of AAVHSC with Robust Distribution to the Central Nervous System and Peripheral Organs with Low Affinity for the Liver
AAVHSC16 Biodistribution Properties in Preclinical Models Demonstrated Potential for Systemic Delivery of Genetic Medicines to Brain, Heart and Muscle
Homology Medicines to Present at Upcoming Conferences on its Gene Editing and Gene Therapy Programs for PKU
BEDFORD, Mass., June 29, 2022 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today participation and presentations at the following conferences:
FIXX ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of May 24, 2022 in the Class Action Filed on Behalf of Homology Medicines, Inc. Limited Shareholders
New York, New York--(Newsfile Corp. - May 24, 2022) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Homology Medicines, Inc. (NASDAQ: FIXX) all...
SHAREHOLDER ALERT FILING DEADLINE TODAY: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Homology Medicines, Inc., of Class Action Lawsuit and Upcoming Deadline - FIXX
NEW YORK , May 24, 2022 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Homology Medicines, Inc. ("Homology" or the "Company") (NASDAQ: FIXX) and certain of ...